Opinion|Videos|July 29, 2024
Melanoma Research Beyond ASCO 2024: Upcoming Advances and Insights
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What are the current challenges in translating clinical trial results into real-world practice for melanoma treatment? How can this process be streamlined?
- Please discuss any other data in melanoma released at ASCO 2024 that you find noteworthy to share with colleagues. (Please be prepared to discuss during the interview)
- Outside of ASCO 2024, what ongoing research efforts are you most excited for in the treatment and management of melanoma? What can we look forward to through the end of the year and beyond?
Advertisement
Related to this article
FDA approved belzutifan plus lenvatinib for advanced ccRCC after PD-1/PD-L1 therapy, expanding treatment options for those with disease progression.
A 3-year registry found dupilumab controlled atopic dermatitis (AD) in most children, though those under 6 years were likelier to stop treatment.
Machine learning identified age, BMI, income, and reproductive factors as key predictors of overactive bladder risk among US women.
Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.
Boarding admitted patients on inpatient floor hallways can alleviate emergency department (ED) crowding. Outcomes tend to be positive, but the published evidence is weak, according to this systematic review.
Accelerated approvals, surrogate end points, and high drug costs are reshaping cancer center formulary decisions, explained panelists at PCOC.
Most community oncology practices now administer bispecific antibodies in-office, but reimbursement gaps remain a top barrier, a survey finds.
Tammy Lundstrom, MD, JD, discusses the new childhood vaccine order, single-dose MMR access concerns, and the measles resurgence.
Advertisement
Advertisement
Trending on AJMC
1
Perceptions About CGMs Among Primary Care Physicians and Endocrinologists
2
COVID-19 or Flu? Symptoms Alone Can't Tell: Tammy Lundstrom, MD, JD
3
Surrogate End Points, Drug Costs Complicate Oncology Formularies
4
Oncology Patients in Clinical Trials: A Health Care Cost Analysis
5